Skoči na glavni sadržaj

Pregledni rad

https://doi.org/10.2478/aiht-2018-69-3204

Sodium-glucose cotransporters: new targets of cancer therapy?

Ivana Vrhovac Madunić ; Institute for Medical Research and Occupational Health, Ksaverska cesta 2, 10000 Zagreb, Croatia
Josip Madunić ; Division of Molecular Biology, Department of Biology, Faculty of Science, University of Zagreb, Zagreb, Croatia
Davorka Breljak ; Institute for Medical Research and Occupational Health, Ksaverska cesta 2, 10000 Zagreb, Croatia
Dean Karaica ; Institute for Medical Research and Occupational Health, Ksaverska cesta 2, 10000 Zagreb, Croatia
Ivan Sabolić ; Institute for Medical Research and Occupational Health, Ksaverska cesta 2, 10000 Zagreb, Croatia


Puni tekst: engleski pdf 667 Kb

str. 278-284

preuzimanja: 608

citiraj


Sažetak

Glucose, the key source of metabolic energy, is imported into cells by two categories of transporters: 1) facilitative glucose transporters (GLUTs) and 2) secondary active sodium-glucose cotransporters (SGLTs). Cancer cells have an increased demand for glucose uptake and utilisation compared to normal cells. Previous studies have demonstrated the overexpression of GLUTs, mainly GLUT1, in many cancer types. As the current standard positron emission tomography (PET) tracer 2-deoxy-2-(18F)fluoro-D-glucose (2-FDG) for imaging tumour cells via GLUT1 lacks in sensitivity and specificity, it may soon be replaced by the newly designed, highly sensitive and specific SGLT tracer α-methyl-4-(F-18)fluoro-4-deoxy-Dglucopyranoside (Me-4FDG) in clinical detection and tumour staging. This tracer has recently demonstrated the functional activity of SGLT in pancreatic, prostate, and brain cancers. The mRNA and protein expression of SGLTs have also been reported in colon/colorectal, lung, ovarian, head, neck, and oral squamous carcinomas. So far, SGLTs have been poorly investigated in cancer, and their protein expression and localisation are often controversial due to a lack of specific SGLT antibodies. In this review, we describe current knowledge concerning SGLT1 and SGLT2 (over)expression in various cancer types. The findings of SGLTs in malignant cells may help in developing novel cancer therapies with SGLT2 or SGLT1/SGLT2 inhibitors already used in diabetes mellitus treatment.

Ključne riječi

brain cancer, Na+-dependent glucose transporters, pancreatic cancer, positron emission tomography, prostate cancer, SGLT inhibitors

Hrčak ID:

213618

URI

https://hrcak.srce.hr/213618

Podaci na drugim jezicima: hrvatski

Posjeta: 1.243 *